IL123330A - Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them - Google Patents

Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them

Info

Publication number
IL123330A
IL123330A IL12333094A IL12333094A IL123330A IL 123330 A IL123330 A IL 123330A IL 12333094 A IL12333094 A IL 12333094A IL 12333094 A IL12333094 A IL 12333094A IL 123330 A IL123330 A IL 123330A
Authority
IL
Israel
Prior art keywords
alkyl
hydrogen
nucleosides
oligonucleotides
preparation
Prior art date
Application number
IL12333094A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL123330A publication Critical patent/IL123330A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL12333094A 1993-05-12 1994-05-10 Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them IL123330A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH146793 1993-05-12
IL10960594A IL109605A (en) 1993-05-12 1994-05-10 Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IL123330A true IL123330A (en) 1999-12-31

Family

ID=4211171

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12333094A IL123330A (en) 1993-05-12 1994-05-10 Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them
IL10960594A IL109605A (en) 1993-05-12 1994-05-10 Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them
IL12333098A IL123330A0 (en) 1993-05-12 1998-02-17 Nucleosides having 2'-ether group their preparation and their use in the production of oligonucleotides

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL10960594A IL109605A (en) 1993-05-12 1994-05-10 Oligonucleotides having 2'-ether groups their use as diagnostics and pharmaceutical compositions containing them
IL12333098A IL123330A0 (en) 1993-05-12 1998-02-17 Nucleosides having 2'-ether group their preparation and their use in the production of oligonucleotides

Country Status (11)

Country Link
US (1) US5969116A (xx)
EP (1) EP0626387B1 (xx)
JP (1) JP4012579B2 (xx)
CN (1) CN1100728A (xx)
AT (1) ATE177430T1 (xx)
AU (1) AU687796B2 (xx)
CA (1) CA2123241C (xx)
DE (1) DE59407895D1 (xx)
DK (1) DK0626387T3 (xx)
ES (1) ES2128535T3 (xx)
IL (3) IL123330A (xx)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
ES2203635T3 (es) * 1994-04-27 2004-04-16 Novartis Ag Nucleosidos y oligonucleotidos con grupos 2'-eter.
AU5359496A (en) * 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) * 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US20110028350A1 (en) * 1995-12-15 2011-02-03 Affymetrix, Inc. Photocleavable protecting groups
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
AU725262B2 (en) 1996-02-14 2000-10-12 Isis Pharmaceuticals, Inc. Sugar-modified gapped oligonucleotides
CA2256765A1 (en) 1996-06-06 1997-12-11 Novartis Ag 2'-substituted nucleosides and oligonucleotide derivatives
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
AU738352B2 (en) * 1997-04-30 2001-09-13 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced bioavailability
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
US6093807A (en) * 1999-03-19 2000-07-25 Isis Pharmaceuticals, Inc. Sugar-modified 7-deaza-7-substituted oligonucleotides
CA2421732A1 (en) * 2000-09-11 2002-03-14 Affymetrix, Inc. Photocleavable protecting groups
US20030027169A1 (en) * 2000-10-27 2003-02-06 Sheng Zhang One-well assay for high throughput detection of single nucleotide polymorphisms
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
EP1560840B1 (en) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US7297686B2 (en) * 2004-11-16 2007-11-20 Hwang David L Chromium complex with insulin-like activity
US8338093B2 (en) * 2004-12-31 2012-12-25 Affymetrix, Inc. Primer array synthesis and validation
US7547775B2 (en) 2004-12-31 2009-06-16 Affymetrix, Inc. Parallel preparation of high fidelity probes in an array format
ZA200709237B (en) 2005-05-05 2009-04-29 Antisense Pharma Gmbh Dosage of oligonucleotides
RU2483057C2 (ru) 2006-06-28 2013-05-27 Ньюселис Инк. Смеси жирных кислот и их применение
US7820810B2 (en) 2007-03-19 2010-10-26 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted purine nulceosides
WO2009067243A2 (en) 2007-11-20 2009-05-28 Isis Pharmaceuticals Inc. Modulation of cd40 expression
WO2009068617A1 (en) 2007-11-30 2009-06-04 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
CN102016036B (zh) 2008-02-11 2015-04-08 阿克赛医药公司 经修饰的RNAi多核苷酸及其用途
UA105362C2 (xx) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх Похідні 1-гетероцикліл-1,5-дигідропіразоло$3,4-d]піримідин-4-ону та їх застосування як модулятори pde9a$производные 1-гетероциклил-1,5-дигидропиразоло$3,4-d] пиримидин-4-она и их применение в качестве модуляторов pde9a
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
EP3336188B1 (en) 2008-09-22 2020-05-06 Phio Pharmaceuticals Corp. Reduced size self-delivering rnai compounds
AU2009308217B2 (en) 2008-10-24 2016-01-21 Ionis Pharmaceuticals, Inc. 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
AU2010221419B2 (en) * 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
ES2460019T3 (es) 2009-03-31 2014-05-13 Boehringer Ingelheim International Gmbh Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rana disorder in cutaneous and fibrotic symptoms
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US9156873B2 (en) 2010-04-28 2015-10-13 Isis Pharmaceuticals, Inc. Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
CN103154014B (zh) 2010-04-28 2015-03-25 Isis制药公司 修饰核苷、其类似物以及由它们制备的寡聚化合物
EP2625186B1 (en) 2010-04-28 2016-07-27 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en) 2010-04-29 2013-06-20 Alnylam Pharmaceuticals, Inc. Lipid formulated single stranded rna
HUE033378T2 (en) 2010-08-12 2017-11-28 Boehringer Ingelheim Int 6-Cycloalkyl-1,5-dihydro-pyrazolo [3,4-D] pyrimidin-4-one and their use as PDE9A inhibitors
EP2453017A1 (en) 2010-11-12 2012-05-16 Antisense Pharma GmbH Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN102993255B (zh) * 2011-09-19 2016-02-10 上海兆维科技发展有限公司 2’-o-(2-甲氧乙基)-5-甲基尿苷和2’-o-(2-甲氧乙基)-5-甲基胞苷及其衍生物的制备及其纯化方法
WO2014178082A1 (en) * 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research Novel 2'/3'/5'-(r/s)-serinyl functionalized oligonucleotides
EP3011028B1 (en) 2013-06-21 2019-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
WO2017007825A1 (en) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
EP3418289A4 (en) 2016-02-17 2019-10-30 Tokyo Institute of Technology ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
CN111819285B (zh) 2018-01-09 2024-08-09 希博斯美国有限公司 防碎基因和突变
WO2019182037A1 (ja) 2018-03-20 2019-09-26 国立大学法人東京工業大学 毒性が低減されたアンチセンスオリゴヌクレオチド
JPWO2023027065A1 (xx) 2021-08-24 2023-03-02
CN118076620A (zh) 2021-09-30 2024-05-24 日产化学株式会社 2’修饰嘧啶核苷的制造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
EP0266099A3 (en) * 1986-10-28 1990-09-19 The Johns Hopkins University Oligonucleoside alkyl or arylphosphonate derivatives capable of crosslinking with or cleaving nucleic acids
AU636573B2 (en) * 1988-02-26 1993-05-06 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
ATE269870T1 (de) * 1989-10-24 2004-07-15 Isis Pharmaceuticals Inc 2'-modifizierte oligonukleotide
CA2073500C (en) * 1990-01-11 2008-03-25 Phillip Dan Cook Compositions and methods for detecting and modulating rna activity and gene expression
WO1993013121A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
DK0549615T3 (da) * 1990-08-13 2006-07-03 Isis Pharmaceuticals Inc Sukkermodificerede oligonukleotider der påviser og modulerer genekspression
AU4684993A (en) * 1992-07-23 1994-02-14 Isis Pharmaceuticals, Inc. Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof

Also Published As

Publication number Publication date
ATE177430T1 (de) 1999-03-15
CA2123241C (en) 2007-02-13
IL109605A (en) 1999-12-31
CA2123241A1 (en) 1994-11-13
AU687796B2 (en) 1998-03-05
AU6304494A (en) 1994-11-17
JP4012579B2 (ja) 2007-11-21
EP0626387A1 (de) 1994-11-30
EP0626387B1 (de) 1999-03-10
US5969116A (en) 1999-10-19
JPH072889A (ja) 1995-01-06
ES2128535T3 (es) 1999-05-16
DK0626387T3 (da) 1999-09-27
IL109605A0 (en) 1994-08-26
CN1100728A (zh) 1995-03-29
DE59407895D1 (de) 1999-04-15
IL123330A0 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
IL123330A (en) Nucleosides having 2'-ether group their preparation their use in the production of oligonucleotides and pharmaceutical compositions containing them
BG95575A (bg) 3'-(2')-амино-и тиолмодифицирани, свързани с флуоресциращо багрило нуклеозиди,нуклеотиди и олигонуклеотиди и метод за тяхното получаване и приложението им
CA2051239A1 (en) Prodrugs of phosphonates
FI930753A (fi) Nya fosfolipidderivat av nukleosider, deras framstaellning och deras anvaendning saosom antivirala laekemedel
CA2143636A1 (en) Derivatives of valproic and 2-valproenoic acid amides and use as anticonvulsants
CA2081299A1 (en) Foaming agent composition and process
SG47761A1 (en) Antiretroviral enantiomeric nucleotide analogs
DE4223438A1 (de) Cyclische oligonucleotidphosphorthioate
MX9700249A (es) Compuestos ariltios como agentes antibacteriales yantivirales.
IL115746A (en) Polyanionic benzylglcosides and pharmaceutical compositions containing them
ES8301927A1 (es) Procedimiento de preparacion de acidos azabiciclohexano car-boxilicos y de sus sales
EP0482071A4 (en) New antiviral agents
HUT61773A (en) Process for producing spicamycin derivatives and pharmaceutical compositions containing them as active components
DK0816368T3 (da) Kemisk phosphorylering af oligonukleotider og reaktanter anvendt dertil
ZA942964B (en) Pyrrolopyrazine compounds processes for their preparation and the pharmaceutical compositions which contain them
HUT45541A (en) Plant protecting compositions containing ester of phosphoric acid as active component and process for producing the active component
IE821315L (en) PREPARATION OF 5,6,7,7a-TETRAHYDRO-4H-THIENO-£3,2-c|¹PYRIDIN-2-ONES
ES8609184A1 (es) Procedimiento de preparar agentes de fluoracion de compuestos organicos.
GR3015604T3 (en) Novel organo-tin compounds having anti-tumour activity and anti-tumour compositions.
JPS6422823A (en) Antiulcer agent
ES8302702A1 (es) Procedimiento para la produccion de nuevos compuestos de lactama.
TW368519B (en) Anhydrous fluorescent whitening agent composition
WO1994009011A1 (de) Quartäre ammoniumgruppen enthaltende siloxanderivate, verfahren zu ihrer herstellung und ihre verwendung
GR3019075T3 (en) Inhibitor of herpes simplex viral thymidine kinase
ES8205811A1 (es) Procedimiento para la preparacion de compuestos de triorganoestano-triacina

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees